Compare TPVG & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | CRBP |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 184.4M |
| IPO Year | 2013 | 2014 |
| Metric | TPVG | CRBP |
|---|---|---|
| Price | $5.57 | $8.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.90 | ★ $45.50 |
| AVG Volume (30 Days) | 218.4K | ★ 671.5K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 17.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $24.00 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $4.48 | $6.73 |
| 52 Week High | $7.50 | $20.56 |
| Indicator | TPVG | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 44.89 |
| Support Level | $5.33 | $7.62 |
| Resistance Level | $5.62 | $8.54 |
| Average True Range (ATR) | 0.14 | 0.58 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 63.29 | 38.19 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.